BioAge Labs
NASDAQ: BIOARichmond, US · Delaware corporation · 9 known investors
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.
Founders & leadership
KF

Kristen Fortney, PhDCo-Founder, CEO
EM

Eric Morgen, MDCo-Founder, COO
EM
Eric MorgenDirector
DG
Dov GoldsteinExecutive Officer
JC
Jason ColomaDirector
KF
Kristen FortneyExecutive Officer, Director
RH
Rehka HemrajaniDirector
PE
Patrick EnrightDirector
VP
Vijay PandeDirector
JH
James HealyDirector
Investors · 9
Andreessen HorowitzMenlo Park · $500K – $50Mvia Vijay Pande · board
Elad GilSan Francisco · $100K – $10M
Felicis VenturesSan Francisco · $500K – $15M
IA Seed VenturesBerkeley
Longitude CapitalMenlo Park · $10M – $30M
OrbiMedNew York · $1M – $75M
Sofinnova VenturesMenlo Park · $100K – $15M
Pear VCreportedSan Francisco · $150K – $4M
RA CapitalreportedBoston
Competitors · 8
by search overlapCowles_Investments_StemCentrx69 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Diabetes Prevention Program68 shared keywords
PatSnap52 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Conor Walsh51 shared keywordsHarvard University is a higher-education and research institution whose schools and faculty conduct medical and scientific research across areas such as chronic disease, public health, and engineering. The page highlights research on conditions including cardiovascular disease, chronic pain, lung disease, and tissue engineering.
Endpoints41 shared keywords
Stanford blockchain41 shared keywords
Czytaj więcej36 shared keywords
Concord Communications35 shared keywords
Companies competing with BioAge Labs for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$194.4MraisedFeb 2024 · 32 investors · BiotechnologyRule 506(b)
▶$194.4MraisedFeb 2024 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric MorgenDirector
- Dov GoldsteinExecutive Officer
- Jason ColomaDirector
- Kristen FortneyExecutive Officer, Director
- Patrick EnrightDirector
- Vijay PandeDirector
- Rehka HemrajaniDirector
- James HealyDirector
- Offering amount
- $194.4M
- Amount sold
- $194.4M
- Minimum investment
- $3
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Longevity Biotech Market: 35 Funding Deals (Full List 2024-2026) (2026) – New Market Pitchnewmarketpitch.com · 2026
- Top Longevity Biotech Startups by Fundraising (2026) – New Market Pitchnewmarketpitch.com · 2026
- Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102 - Simply Wall St Newssimplywall.st · 2026
- BioAge Labs principal accounting officer sells $1.57m in stock By Investing.comca.investing.com · 2026
- BioAge Labs Secures $115 Million Series | Signalbasetrysignalbase.com · 2026